

## Evolution of the composition of the Board of Directors of AMOEBA

**Chassieu (France), June 24, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB)**, producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces the provisional appointment of Mr. Philippe Dujardin as an independent director of the Board of Directors, to replace Mr Pascal Reber for the remainder of his predecessor's term of office, i.e. until the Ordinary General Meeting called to approve the financial statements for the year ending 31 December 2022, subject to ratification by the next Ordinary General Meeting.

After examining the situation of Mr Philippe Dujardin with regard to the independence criteria defined by the MiddleNext Code to which AMOEBA refers, the Board of Directors qualified Mr Philippe Dujardin as an independent director.

### **Philippe DUJARDIN**

Philippe Dujardin has 30 years of experience in growth companies. Previously Deputy CEO of Awabot, Chief Financial Officer of Erytech Pharma, he was also Director of Financing and Investor Relations at Infogrames / Atari Group.

He joined BOOSTHEAT in 2014 as C.F.O and held the positions of Head of Development of BOOSTHEAT SA (partnerships, offers, international development...) and Chief Executive Officer of BOOSTHEAT France.

Philippe Dujardin is a graduate of the Ecole Supérieure de Commerce de Reims and of the Institut d'Etudes Politiques de Lyon.

Mr Pascal Reber will continue to bring his extensive experience and expertise to the service of the Company and will attend future meetings of the Board of Directors in a consultative role as censor.

*"I welcome Philippe Dujardin to our Board of Directors. I am delighted with his arrival, which reinforces the good governance of the Company and complements the skills already present on the Board by bringing his solid financial expertise and his experience in the management of innovative companies. I would like to thank Pascal Reber for his support and involvement in the development of the company over the past 7 years", says Fabrice Plasson, Chairman and CEO of Amoeba.*

**About AMOEBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-nature.com](http://www.amoeba-nature.com).

*(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

*(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets*

*(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

*(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

**Contacts:**

**Amoéba**

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

[v.filiatre@amoeba-nature.com](mailto:v.filiatre@amoeba-nature.com)

**Calyptus**

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

[amoeba@calyptus.net](mailto:amoeba@calyptus.net)